Israeli scientist says Covid-19 could be treated for under $1/day
jpost.com
jpost.com
Page 2:
> On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31).
Page 21:
> 57 were assigned to Ivermectin group, 7 had SARS-CoV-2 RT-PCR with Ct value >35 in the two first tests, 3 were lost for follow up, 47 were eligible for analysis
> 59 were assigned to Placebo group, 14 had SARS-CoV-2 RT-PCR with Ct value >35 in the two first tests, 3 were lost for follow up, 42 were eligible for analysis
Note that "Ct >35" means that the viral charge was so low that after amplifying the virus 35 times they weren't able to detect it. If we add them to the people with a good outcome, we get:
41 out of 54 (76%) patients in the ivermectin arm reached the "endpoint", compared to 35 out of 56 (61%) in the placebo arm.
And this is probably not statistically significant any more.
IN ADDITION, the study looked at culture viability, meaning how infectious the patients were, and found that only 13% of ivermectin patients were infectious after six days, compared with 50% of the placebo group – almost four times as many."
It calls for a bigger study.